The WACC of Sun Pharma Advanced Research Co Ltd (SPARC.NS) is 18.9%.
| Range | Selected | |
| Cost of equity | 18.20% - 21.10% | 19.65% |
| Tax rate | -% - -% | -% |
| Cost of debt | 7.50% - 11.60% | 9.55% |
| WACC | 17.4% - 20.4% | 18.9% |
| Category | Low | High |
| Long-term bond rate | 6.9% | 7.4% |
| Equity market risk premium | 8.3% | 9.3% |
| Adjusted beta | 1.36 | 1.42 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 18.20% | 21.10% |
| Tax rate | -% | -% |
| Debt/Equity ratio | 0.08 | 0.08 |
| Cost of debt | 7.50% | 11.60% |
| After-tax WACC | 17.4% | 20.4% |
| Selected WACC | 18.9% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for SPARC.NS:
cost_of_equity (19.65%) = risk_free_rate (7.15%) + equity_risk_premium (8.80%) * adjusted_beta (1.36) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.